2.6. Safety
ADVERSE EVENTS, BLOOD
Blood samples for safety parameters (clinical biochemistry and hematology) were collected at visit 1 (screening), visit 2 (baseline), and visit 5 (12 weeks). The samples were analyzed by Eurofins Biomnis, Dublin, Ireland. Safety was also assessed via monitoring of adverse events (Aes) and physical examinations. The subjects were also questioned about their medication history during the screening visit and thereafter queried at each visit about the use of any concomitant medications. 